World Lung Day 2020 at the Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular Physiology
2020; American Physical Society; Volume: 319; Issue: 3 Linguagem: Inglês
10.1152/ajplung.00371.2020
ISSN1522-1504
Autores Tópico(s)Chronic Obstructive Pulmonary Disease (COPD) Research
ResumoEditorialWorld Lung Day 2020 at the Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular PhysiologySue C. Bodine and Rory E. MortySue C. BodineDivision of Endocrinology and Metabolism, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa and Rory E. MortyDepartment of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyDepartment of Internal Medicine (Pulmonology), University of Giessen and Marburg Lung Center, Justus Liebig University Giessen, member of the German Center for Lung Research (DZL), Giessen, GermanyPublished Online:04 Sep 2020https://doi.org/10.1152/ajplung.00371.2020This is the final version - click for previous versionMoreSectionsPDF (82 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat The Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular Physiology are two publications of the American Physiological Society (APS) that represent the APS Respiration Section. Both journals have a long and rich history of publishing high-quality investigational reports in areas of respiration, lung, and airway physiology that are pertinent to every aspect of lung health and disease highlighted on World Lung Day. The common forerunner of both journals was the American Journal of Physiology, where the first “lung” article was a report on the correction of a pneumothorax with a Meltzer pleural cannula, penned by Dr. Samuel Meltzer himself, that was published in 1898 (29). Since then, the Journal of Applied Physiology splintered off from the American Journal of Physiology in 1948 (20). Some 40 years later, the first issue of an APS journal dedicated to lung cellular and molecular biology was published in 1989—the American Journal of Physiology-Lung Cellular and Molecular Physiology, in which the inaugural article (43) recalled John Clements’ 1961 Bowditch Lecture on surfactant (7).Today, both journals publish reports on any aspect of respiration, lung, and airway physiology, with the scope of the Journal of Applied Physiology extending well beyond the respiratory system to encompass all aspects of applied physiology, with particular emphasis on integrative environmental and exercise physiology. In contrast, the American Journal of Physiology-Lung Cellular and Molecular Physiology restricts its scope to articles dealing with any aspect of the physiology of the respiratory system, from the nose to the alveoli. The thematic diversity of articles published within both journals includes analyses of lung and airways structure; structure-function relationships; chest wall and lung mechanics and the control of breathing; ion and fluid homeostasis; and lung and airways development. The physiology of disease is extensively covered, including pathophysiology related to acute lung injury; pneumonia and pulmonary edema; infection, inflammation, and immune cell biology; sepsis; fibrosis and fibroblast biology; epithelial barrier function and epithelial cell biology; asthma and airways disease; cystic fibrosis; emphysema; pulmonary vascular disease, including endothelial cell biology; cardiac causes and consequences of lung disease; lung cancer; lung transplantation; and disorders of lung development. Over the past year, manuscripts have been submitted from 53 countries to the Journal of Applied Physiology and from 39 countries to the American Journal of Physiology-Lung Cellular and Molecular Physiology.Both journals attract topics of special interest through Calls for Papers. The Calls for Papers that are currently open at both journals are listed in Table 1, which includes the first APS cross-journal Call for Papers, “Deconstructing Organs: Single-Cell Analyses, Decellularized Organs, Organoids, and Organ-on-a-Chip Models,” involving 10 journals from the APS publications portfolio (1). That Call for Papers aims to attract the submission of manuscripts that deal with current state-of-the art approaches to studying the physiology of the respiratory system, including single-cell analysis, organotypic cultures of precision-cut lung and airways slices, decellularized lung scaffolds, organoids and other three-dimensional cell cultures, and organ-on-a-chip models.Table 1. Currently open Calls for Papers at the Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular Physiology as of 1 August 2020TitleDeadline*Cross-Journal Call for Papers Deconstructing Organs: Single-Cell Analyses, Decellularized Organs, Organoids, and Organ-on-a-Chip Models31 December 2021Journal of Applied Physiology Call for Comments—Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies18 August 2020 Highlighted Topic: Physiology of Thermal Therapy1 September 2020 Call for Comments—Point:Counterpoint: Investigators should/should not control for menstrual cycle phase when performing studies of vascular control that include women11 September 2020American Journal of Physiology-Lung Cellular and Molecular Physiology Electronic Cigarettes: Not All Good News?31 December 2020 Extracellular Vesicles in Lung Health, Disease, and Therapy31 December 2020 Joint Call for Papers with Physiological Reports: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection31 December 2020 Senescence in the Lung31 December 2020 Circadian Rhythms in the Lung1 April 2021*Deadlines are subject to extension. Up-to-date information on Calls for Papers may be found at https://journals.physiology.org/Calls.Topics for upcoming Calls for Papers that are still in planning to be launched before the end of 2020 include a cross-journal Call for Papers on interorgan communication in physiology and disease. Topics of open Calls for Papers at the Journal of Applied Physiology that address respiratory physiology include severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus-viral receptor interactions that affect skeletal muscle viral susceptibility and myopathies as well as consideration of the physiology of thermal therapy (Table 1). Upcoming Calls for Papers at the Journal of Applied Physiology that are still in planning and will be launched before the end of 2020 include a Call for Papers on recovery from coronavirus disease 2019 (COVID-19) and the long-term health and performance consequences. Topics of open Calls for Papers at the American Journal of Physiology-Lung Cellular and Molecular Physiology include a Call for Papers on SARS-CoV-2 and COVID-19, as well as separate Calls for Papers on e-cigarettes, nicotine, and heated tobacco products; extracellular vesicles; cell senescence; and circadian rhythms (Table 1). Furthermore, Calls for Papers are currently in development at the American Journal of Physiology-Lung Cellular and Molecular Physiology on cellular metabolism, mitochondrial dysfunction, and reverse translation (bedside to bench) as well as a Call for Papers that will serve as a tribute to the recently deceased Dr. Ewald Weibel (32), which will link genetics to function. It is entertaining to reflect that the Foreword of the inaugural issue of the Journal of Applied Physiology (20), penned in 1948, explained the need to create a new journal to expand the increasing scope of new and emerging topics in physiology: “For example, physiological aspects of […] aging and the aging process, and of metabolism will come within the scope of this Journal.” Seventy-two years later, these two topics form the basis of one current (cell senescence) and one planned (cellular metabolism and mitochondrial dysfunction) Call for Papers at the American Journal of Physiology-Lung Cellular and Molecular Physiology!Without question, the dominating theme in pulmonary science and medicine in 2020 has been SARS-CoV-2 (48), the etiological agent of zoonotic COVID-19 (18). The APS was quick to respond to the pressing need for the rapid and wide dissemination of knowledge related to COVID-19 pathophysiology. To this end, the APS established a “Coronavirus-Related Collection” of papers (available at: https://journals.physiology.org/covid19), which is a list of all COVID-19-related articles published in the APS portfolio of journals, and that list is updated daily. All of those articles are immediately and freely available to everybody. The advent of COVID-19 brought with it laboratory shutdowns and the re-deployment of clinically active lung scientists to COVID-19 management stations and was thus not without impact on our contributing authors and our reviewers. With these issues in mind, the APS developed policy to give our contributing scientists increased flexibility in responding to author critiques and to give our reviewers an extended time frame in which to complete their reviews. These changes were outlined in a letter penned by Ms. Colette E. Bean, our Chief Publishing Officer, and Dr. David Gutterman, our APS Publications Committee Chair (16). Furthermore, because of the cancelation of numerous scientific meetings, including Experimental Biology 2020, the APS acknowledged that many researchers would be looking for alternate ways to present their recent research. In response to that need, a new article type—the Mini-Review—was introduced, which is particularly targeted at trainees and early-career investigators. Both journals have now published their first Mini-Review articles: “Let’s talk about sex in the context of COVID-19” (11) in the Journal of Applied Physiology and “Heparin as a therapy for COVID-19: current evidence and future possibilities” (17) in the American Journal of Physiology-Lung Cellular and Molecular Physiology.As journals affiliated with the APS Respiration Section, both the Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular Physiology issued Calls for Papers addressing aspects of COVID-19 pathophysiology. In line with muscle physiology being a key theme at the Journal of Applied Physiology, a Call for Comments, “Viewpoint: The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies,” was issued. That Call for Papers was in response to a recently published article, “The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies” (8). Commentaries accepted in response to this Call for Papers will be published in the October 2020 issue of the Journal of Applied Physiology. Additionally, a joint Call for Papers, “The Pathophysiology of COVID-19 and SARS-CoV-2 Infection,” was issued by the American Journal of Physiology-Lung Cellular and Molecular Physiology together with our sister journal, Physiological Reports (30). Coverage of COVID-19 has not been restricted to these three APS journals. The Calls for Papers listed above are currently complemented by an existing Call for Papers at the American Journal of Physiology-Cell Physiology, “Virus-Host Cell Interactions and the Viral Life Cycle: Basic Science to Therapeutics,” which has also attracted COVID-19-related articles (40). Indeed, most journals within the diverse APS journal portfolio have by now contributed high-quality reports to the body of scientific literature on COVID-19, and all of these articles are listed at the “Coronavirus-Related Collection” of papers (available at: https://journals.physiology.org/covid19). These articles have spanned themes as diverse as risk factors for COVID-19 susceptibility (19), gastrointestinal issues in patients with COVID-19 (47), maternal and neonatal responses to COVID-19 (15), the kidney as a target for SARS-CoV-2 (24), the utility of oral rinses to target the viral lipid envelope in SARS-CoV-2 infection (31), using artificial intelligence and machine learning to fight COVID-19 (2), the cardiovascular consequences of COVID-19 (41), recommendations for transition to online instruction in physiology (34), and a perspective on “The New Normal—Life in a Pandemic” (39). These articles on COVID-19 are widely read, both within and outside the scientific community. For example, within one month of online publication (as of 25 July 2020) of “Understanding the age divide in COVID-19: why are children overwhelmingly spared?” (22) in the American Journal of Physiology-Lung Cellular and Molecular Physiology, that article had been picked up by 37 news outlets. The topical nature of COVID-19 studies also comes at a price: the deluge of COVID-19-related articles that continue to flood the scientific literature (33) has caused concerns to be raised about the importance of publishing non-COVID-19 research during COVID-19, to avoid a “destruction of a diversified literature” (6). Both journals, together with all other APS journals, continue to publish a healthy balance of COVID-19 versus non-COVID-19 articles. Indeed, between 1 January and 1 August 2020, COVID-19-related articles accounted for 2% of all articles published in the Journal of Applied Physiology and 11% of all articles published in the American Journal of Physiology-Lung Cellular and Molecular Physiology.The tremendous pace at which research into SARS-CoV-2 and COVID-19 has been conducted—to rapidly advance our understanding of disease pathophysiology—has challenged academic publishing in many ways (42), most notably how to sustain integrity while under pressure to publish quickly. Concerns have been raised about the promotion of pseudoscience (including homeopathy and energy healing) (5, 37), contributing to the COVID-19 “infodemic” (9), as have as concerns about superficial editorial oversight and less-than-robust peer review (4, 14). Indeed, a wave of article retractions has trailed the tsunami of COVID-19-related articles appearing in the scientific literature (38), which include retracted papers on hydroxychloroquine in The Lancet (27, 28) and on cardiovascular disease, drug therapy, and mortality related to COVID-19 in The New England Journal of Medicine (25, 26). Other times, unretracted articles are the object of fierce criticism (36) and discussion (23, 44) within the same journal in which they are published (12). The Editors of all APS publications, together with the staff of the Publications Division, are cognizant of the need to thematically balance journal content and to ensure scientific rigor through robust editorial oversight and peer review of manuscripts. This topic has been addressed directly in the pages of the American Journal of Physiology-Lung Cellular and Molecular Physiology (46).The implementation of diversity, equity, and inclusion (DEI) is a key priority of the Editors-in-Chief at both journals. The year 2020 saw Dr. Melissa L. Bates take over the reins of leadership of our Respiration Section from her predecessor, Dr. Gregory A. Funk. As Chair of the APS Respiration Section, Dr. Bates, together with Dr. Karla K. V. Haack, Chair of the APS Diversity and Inclusion Committee, penned an Editorial, “Everyone must be able to breathe: a plan to support diversity and inclusion in respiratory physiology” (3). This Editorial laid out a plan that is currently being implemented at both journals to introduce new, and further support current, DEI initiatives: watch this space! Heightened consideration of DEI has never been more important, a sentiment underscored by the fact that—like most other areas of respiration physiology—COVID-19 has not been without impact on DEI. Gender inequalities have already been noted in COVID-19 research authorship (35), and data already suggest that female researchers, particularly those at early-career stages, are the hardest hit (13).Reports on respiration, lung, and airway (patho)physiology published in pages of the Journal of Applied Physiology and the American Journal of Physiology-Lung Cellular and Molecular Physiology continue to advance our knowledge about the physiological mechanisms at play in healthy and diseased lungs. The editorial leadership of both journals strives to keep journal content current, and at the leading edge of discovery, by issuing Calls for Papers to attract original research and review-type articles, which can then be discussed in a variety of editorial mechanisms, at the social media facilities of both journals, and (in a post-COVID-19 world) at our APS Meetings and Events. This provides an ideal constellation for the interaction of the APS and our journal leadership with the communities that we serve, including our contributing authors, reviewers, and readers, to promote and report scientific discovery in all areas of (patho)physiology that are relevant to World Lung Day. These areas have been nicely highlighted in the accompanying Editorials by the leadership of the Forum of International Respiratory Societies (the organization that hosts World Lung Day) (10), by the President of the European Respiratory Society (ERS), penned together with a number of Principal Investigators who are ERS members (45), and by the leadership of the Division of Lung Diseases at the National Institutes of Health (35a). As SARS-CoV-2 and COVID-19 have taught us in 2020, there will always be new things to discover and to understand in respiration, lung, and airway physiology.GRANTSS.C.B. is supported by the National Institutes of Health through Grants R01AR070031, U01AG055133, R01AR071762, and R01AG060637. R.E.M. is supported by the Max Planck Society (MPI-HLR), the German Center for Lung Research (Deutsches Zentrum für Lungenforschung; DZL) (DZL-UGMLC), and the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) through EXC2026 (390649896), SFB1213 (268555672), KFO309 (284237345), Mo1789/1-1 (160966624), and Mo1789/4-1 (420759458).DISCLOSURESS. C. Bodine is the Editor-in-Chief of the Journal of Applied Physiology. R. E. Morty is the Editor-in-Chief of the American Journal of Physiology-Lung Cellular and Molecular Physiology. Both Editors are compensated by the American Physiological Society for their services.AUTHOR CONTRIBUTIONSS.C.B. and R.E.M. drafted manuscript; edited and revised manuscript; and approved final version of manuscript.REFERENCES1. Adams JC, Bell PD, Bodine SC, Brooks HL, Bunnett N, Joe B, Keehan KH, Kleyman TR, Marette A, Morty RE, Ramírez JM, Thomsen MB, Yates BJ, Zucker IH. An American Physiological Society cross-journal Call for Papers on “Deconstructing Organs: Single-Cell Analyses, Decellularized Organs, Organoids, and Organ-on-a-Chip Models”. Am J Physiol Lung Cell Mol Physiol 319: L266–L272, 2020. doi:10.1152/ajplung.00311.2020. Link | ISI | Google Scholar2. Alimadadi A, Aryal S, Manandhar I, Munroe PB, Joe B, Cheng X. Artificial intelligence and machine learning to fight COVID-19. Physiol Genomics 52: 200–202, 2020. doi:10.1152/physiolgenomics.00029.2020. Link | ISI | Google Scholar3. Bates ML, Haack KK. Everyone must be able to breathe: a plan to support diversity and inclusion in respiratory physiology. Am J Physiol Lung Cell Mol Physiol 319: L159–L162, 2020. doi:10.1152/ajplung.00269.2020. Link | ISI | Google Scholar4. Bell K, Green J. Premature evaluation? Some cautionary thoughts on global pandemics and scholarly publishing. Crit Public Health 30: 379–383, 2020. doi:10.1080/09581596.2020.1769406.Crossref | ISI | Google Scholar5. Caulfield T. Pseudoscience and COVID-19—we’ve had enough already. Nature. In press. doi:10.1038/d41586-020-01266-z. Crossref | PubMed | Google Scholar6. Chaitoff A. The importance of publishing non-COVID-19 research during COVID-19. J Clin Epidemiol. In press. doi:10.1016/j.jclinepi.2020.06.038. Crossref | PubMed | Google Scholar7. Clements JA. Surface phenomena in relation to pulmonary function. Physiologist 5: 11–28, 1962. PubMed | Google Scholar8. Ferrandi PJ, Alway SE, Mohamed JS. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol (1985). In press. doi:10.1152/japplphysiol.00321.2020. Link | ISI | Google Scholar9. Fleming N. Coronavirus misinformation, and how scientists can help to fight it. Nature 583: 155–156, 2020. doi:10.1038/d41586-020-01834-3. Crossref | PubMed | Google Scholar10. Fong KM, Welte T; Forum of International Respiratory Societies (FIRS). World Lung Day: what, why, and where to? Am J Physiol Lung Cell Mol Physiol. In press. doi:10.1152/ajplung.00364.2020. Link | Google Scholar11. Gargaglioni LH, Marques DA. Let’s talk about sex in the context of COVID-19. J Appl Physiol (1985) 128: 1533–1538, 2020. doi:10.1152/japplphysiol.00335.2020. Link | ISI | Google Scholar12. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949, 2020. doi:10.1016/j.ijantimicag.2020.105949. Crossref | PubMed | ISI | Google Scholar13. Gewin V. The career cost of COVID-19 to female researchers, and how science should respond. Nature 583: 867–869, 2020. doi:10.1038/d41586-020-02183-x. Crossref | PubMed | Google Scholar14. Glasziou PP, Sanders S, Hoffmann T. Waste in COVID-19 research. BMJ 369: m1847, 2020. doi:10.1136/bmj.m1847. Crossref | PubMed | Google Scholar15. Golden TN, Simmons RA. Maternal and neonatal response to COVID-19. Am J Physiol Endocrinol Metab 319: E315–E319, 2020. doi:10.1152/ajpendo.00287.2020. Link | ISI | Google Scholar16. Gutterman D, Bean CE. APS Responds to the COVID-19 Pandemic (Online). Bethesda, MD: American Physiological Society. https://journals.physiology.org/pb-assets/PDFs/APS-COVID-message-1585080439187.pdf [1 August 2020].Google Scholar17. Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol 319: L211–L217, 2020. doi:10.1152/ajplung.00199.2020. Link | ISI | Google Scholar18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, 2020. doi:10.1016/S0140-6736(20)30183-5. Crossref | PubMed | ISI | Google Scholar19. Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev 100: 1065–1075, 2020. doi:10.1152/physrev.00013.2020. Link | ISI | Google Scholar20. Journal of Applied Physiology. Foreword. J Appl Physiol 1: 1–2, 1948. doi:10.1152/jappl.1948.1.1.1.Link | Google Scholar22. Lingappan K, Karmouty-Quintana H, Davies J, Akkanti B, Harting MT. Understanding the age divide in COVID-19: why are children overwhelmingly spared? Am J Physiol Lung Cell Mol Physiol 319: L39–L44, 2020. doi:10.1152/ajplung.00183.2020. Link | ISI | Google Scholar23. Machiels JD, Bleeker-Rovers CP, Ter Heine R, Rahamat-Langendoen J, de Mast Q, Ten Oever J, Bousema T, van Crevel R, Wertheim HF. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks? Int J Antimicrob Agents 56: 106056, 2020. doi:10.1016/j.ijantimicag.2020.106056. Crossref | PubMed | Google Scholar24. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol 318: F1454–F1462, 2020. doi:10.1152/ajprenal.00160.2020. Link | ISI | Google Scholar25. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382: e102, 2020. doi:10.1056/NEJMoa2007621. Crossref | PubMed | Google Scholar26. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 382: 2582, 2020. doi:10.1056/NEJMc2021225. Crossref | PubMed | ISI | Google Scholar27. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. In press. doi:10.1016/S0140-6736(20)31180-6. Crossref | PubMed | Google Scholar28. Mehra MR, Ruschitzka F, Patel AN. Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 395: 1820, 2020. doi:10.1016/S0140-6736(20)31324-6. Crossref | PubMed | Google Scholar29. Meltzer SJ. Demonstration: a simple method for the redistension of the collapsed lung. Am J Physiol 1: ix–x, 1898.Google Scholar30. Morty RE, Ziebuhr J. Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection. Am J Physiol Lung Cell Mol Physiol 318: L1016–L1019, 2020. doi:10.1152/ajplung.00136.2020. Link | ISI | Google Scholar31. O’Donnell VB, Thomas D, Stanton R, Maillard JY, Murphy RC, Jones SA, Humphreys I, Wakelam MJ, Fegan C, Wise MP, Bosch A, Sattar SA. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function 1: zqaa002, 2020. doi:10.1093/function/zqaa002.Crossref | Google Scholar32. Ochs M. “And then I met Ewald Weibel”. Am J Physiol Lung Cell Mol Physiol 319: L403–L407, 2020. doi:10.1152/ajplung.00313.2020. Link | ISI | Google Scholar33. Pericàs JM, Arenas A, Torrallardona-Murphy O, Valero H, Nicolás D. Published evidence on COVID-19 in top-ranked journals: a descriptive study. Eur J Intern Med. In press. doi:10.1016/j.ejim.2020.07.005. Crossref | PubMed | Google Scholar34. Petzold AM. Letter to the Editor: Resources and recommendations for a quick transition to online instruction in physiology. Adv Physiol Educ 44: 217–219, 2020. doi:10.1152/advan.00049.2020. Link | ISI | Google Scholar35. Pinho-Gomes AC, Peters S, Thompson K, Hockham C, Ripullone K, Woodward M, Carcel C. Where are the women? Gender inequalities in COVID-19 research authorship. BMJ Glob Health 5: e002922, 2020. doi:10.1136/bmjgh-2020-002922. Crossref | PubMed | Google Scholar35a. Postow L, Noel P, Lin S, Zhou G, Fessel J, Kiley JP. Diagnosing and treating lung disease at the cellular level. Am J Physiol Lung Cell Mol Physiol. In press. doi:10.1152/ajplung.00372.2020. Link | Google Scholar36. Rosendaal FR. Review of: “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial” Gautret et al. 2010, doi:10.1016/j.ijantimicag.2020.105949. Int J Antimicrob Agents 56: 106063, 2020. doi:10.1016/j.ijantimicag.2020.106063. Crossref | PubMed | Google Scholar37. Scales D, Gorman S, Gorman J. Resist pseudoscience with respect, not ridicule. Nature 582: 32, 2020. doi:10.1038/d41586-020-01626-9. Crossref | PubMed | Google Scholar38. Sengupta S. An editorial perspective on the infamous COVID-19 studies retracted by Lancet and NEJM. Indian J Ophthalmol 68: 1247–1248, 2020. doi:10.4103/ijo.IJO_1853_20. Crossref | PubMed | ISI | Google Scholar39. Sieck GC. Physiology in perspective: the new normal-life in a pandemic. Physiology (Bethesda) 35: 220–221, 2020. doi:10.1152/physiol.00014.2020. Link | ISI | Google Scholar40. Singh KK, Chaubey G, Chen JY, Suravajhala P. Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis. Am J Physiol Cell Physiol 319: C258–C267, 2020. doi:10.1152/ajpcell.00224.2020. Link | ISI | Google Scholar41. South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol 318: H1084–H1090, 2020. doi:10.1152/ajpheart.00217.2020. Link | ISI | Google Scholar42. Teixeira da Silva JA. An alert to COVID-19 literature in predatory publishing venues. J Acad Librariansh 46: 102187, 2020. doi:10.1016/j.acalib.2020.102187. Crossref | PubMed | Google Scholar43. Tierney DF. Lung surfactant: some historical perspectives leading to its cellular and molecular biology. Am J Physiol Lung Cell Mol Physiol 257: L1–L12, 1989. doi:10.1152/ajplung.1989.257.2.L1. Link | ISI | Google Scholar44. Voss A, Coombs G, Unal S, Saginur R, Hsueh PR. Publishing in face of the COVID-19 pandemic. Int J Antimicrob Agents 56: 106081, 2020. doi:10.1016/j.ijantimicag.2020.106081. Crossref | PubMed | Google Scholar45. Wagner DE, Ubags ND, Troosters T, Alejandre Alcazar MA. Fostering the integration of basic respiratory science and translational pulmonary medicine for the future. Am J Physiol Lung Cell Mol Physiol. In press. doi:10.1152/ajplung.00361.2020. Link | Google Scholar46. Welling PA, Batlle D, Byrd JB, Burrell LM, South AM, Sparks MA. Rigor before speculation in COVID-19 therapy. Am J Physiol Lung Cell Mol Physiol 318: L1027–L1028, 2020. doi:10.1152/ajplung.00152.2020. Link | ISI | Google Scholar47. Ye Q, Wang B, Zhang T, Xu J, Shang S. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol 319: G245–G252, 2020. doi:10.1152/ajpgi.00148.2020. Link | ISI | Google Scholar48. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382: 727–733, 2020. doi:10.1056/NEJMoa2001017. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESCorrespondence: R. E. Morty (rory.[email protected]mpg.de). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Related ArticlesWorld health observances in September 2020: sepsis, the lung and heart, and pulmonary fibrosis in focus 04 Sep 2020American Journal of Physiology-Lung Cellular and Molecular PhysiologyWorld Lung Day: what, why, and where to? 04 Sep 2020American Journal of Physiology-Lung Cellular and Molecular PhysiologyFostering the integration of basic respiratory science and translational pulmonary medicine for the future 04 Sep 2020American Journal of Physiology-Lung Cellular and Molecular PhysiologyDiagnosing and treating lung disease at the cellular level 04 Sep 2020American Journal of Physiology-Lung Cellular and Molecular PhysiologyCited ByPromoting our early career members at AJP-Lung: the Editorial Board Fellowship Program and the Next Generation Physiologist Highlights section at our JournalLarissa A. Shimoda, Chunxue Bai, Nathan W. Bartlett, Julie A. Bastarache, Carol Feghali-Bostwick, Susan J. Gunst, Wolfgang M. Kuebler, Eric P. Schmidt, and Rory E. Morty20 October 2021 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 321, No. 5Respiratory diseases are whole body diseases: opportunities for growth in respiratory physiologyMelissa L. Bates7 September 2021 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 321, No. 3Call for Papers on “Lung Diseases in Reverse Translation: Bedside to the Bench”Larissa A. Shimoda and Rory E. Morty3 November 2020 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 319, No. 5World health observances in September 2020: sepsis, the lung and heart, and pulmonary fibrosis in focusClaudio Nardiello and Rory E. Morty4 September 2020 | American Journal of Physiology-Lung Cellular and Molecular Physiology, Vol. 319, No. 3 Press Release E-cigarette Use during Pregnancy Creates Lung Dysfunction in Babies - December 8, 2022 More from this issue > Volume 319Issue 3September 2020Pages L534-L537 Copyright & PermissionsCopyright © 2020 the American Physiological Societyhttps://doi.org/10.1152/ajplung.00371.2020PubMed32755315History Received 3 August 2020 Accepted 3 August 2020 Published online 4 September 2020 Published in print 1 September 2020 KeywordsAmerican Journal of Physiology-Lung Cellular and Molecular PhysiologyCOVID-19diversity, equity, and inclusionJournal of Applied PhysiologyWorld Lung Day Metrics
Referência(s)